- Report
- December 2024
- 146 Pages
Global
From €3595EUR$3,950USD£3,082GBP
- Report
- March 2025
- 316 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- April 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- May 2024
- 130 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- May 2024
- 130 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Report
- February 2025
- 183 Pages
Global
From €4095EUR$4,500USD£3,511GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1365EUR$1,500USD£1,170GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1820EUR$2,000USD£1,560GBP
- Report
- March 2023
- 147 Pages
Global
From €4504EUR$4,949USD£3,861GBP
- Report
- January 2024
- 110 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- July 2022
- 110 Pages
Global
From €1820EUR$2,000USD£1,560GBP
- Report
- May 2022
- 84 Pages
Global
From €1820EUR$2,000USD£1,560GBP
The Back Pain Drug market is a subset of the larger Musculoskeletal Disorders Drugs market. These drugs are used to treat a variety of conditions, including lower back pain, neck pain, and osteoarthritis. Commonly prescribed medications include non-steroidal anti-inflammatory drugs (NSAIDs), muscle relaxants, and opioids. In addition, physical therapy, exercise, and lifestyle modifications are often recommended to help manage pain.
The Back Pain Drug market is highly competitive, with a variety of companies offering products. Some of the major players in the market include Pfizer, GlaxoSmithKline, Merck & Co., Novartis, and Johnson & Johnson. Other companies include Eli Lilly, Sanofi, AstraZeneca, and AbbVie. Show Less Read more
